171 related articles for article (PubMed ID: 32098944)
1. Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis.
Guglielmelli P; Carobbio A; Rumi E; De Stefano V; Mannelli L; Mannelli F; Rotunno G; Coltro G; Betti S; Cavalloni C; Finazzi MC; Thiele J; Cazzola M; Vannucchi AM; Barbui T
Blood Cancer J; 2020 Feb; 10(2):21. PubMed ID: 32098944
[TBL] [Abstract][Full Text] [Related]
2. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients.
Haider M; Gangat N; Lasho T; Abou Hussein AK; Elala YC; Hanson C; Tefferi A
Am J Hematol; 2016 Jun; 91(4):390-4. PubMed ID: 26799697
[TBL] [Abstract][Full Text] [Related]
3. Application of prognostic score IPSET-thrombosis in patients with essential thrombocythemia of a Brazilian public service.
Navarro LM; Trufelli DC; Bonito DR; Del Giglio A; Bollmann PW
Rev Assoc Med Bras (1992); 2016 Oct; 62(7):647-651. PubMed ID: 27925044
[TBL] [Abstract][Full Text] [Related]
4. Comparison between thrombotic risk scores in essential thrombocythemia and survival implications.
Santoro M; Accurso V; Mancuso S; Carlisi M; Raso S; Tarantino G; Di Piazza F; Perez A; Russo A; Siragusa S
Hematol Oncol; 2019 Oct; 37(4):434-437. PubMed ID: 31465530
[TBL] [Abstract][Full Text] [Related]
5. Validation of previous prognostic models for thrombosis and exploration of modified models in patients with essential thrombocythemia.
Hashimoto Y; Nakamae H; Tanaka T; Omura H; Horiuchi M; Yoshimura T; Takakuwa T; Mugitani A; Hirose A; Nakamae M; Koh H; Hino M
Eur J Haematol; 2018 Oct; 101(4):508-513. PubMed ID: 29971894
[TBL] [Abstract][Full Text] [Related]
6. External validation and clinical evaluation of the International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in a large cohort of Chinese patients.
Fu R; Xuan M; Lv C; Zhang L; Li H; Zhang X; Zhang D; Sun T; Xue F; Liu X; Liang H; Zhang L; Yang R
Eur J Haematol; 2014 Jun; 92(6):502-9. PubMed ID: 24460750
[TBL] [Abstract][Full Text] [Related]
7. [Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients].
Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Garcia-Pallarols F; Longarón R; Ancochea À; Besses C
Med Clin (Barc); 2015 Mar; 144(6):247-53. PubMed ID: 25192581
[TBL] [Abstract][Full Text] [Related]
8. Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis.
Rupoli S; Goteri G; Picardi P; Micucci G; Canafoglia L; Scortechini AR; Federici I; Giantomassi F; Da Lio L; Zizzi A; Honorati E; Leoni P
Diagn Pathol; 2015 Apr; 10():29. PubMed ID: 25885405
[TBL] [Abstract][Full Text] [Related]
9. [Clinical evaluation of the revised International Prognostic Score of Thrombosis for essential thrombocythemia (IPSET-thrombosis) in a cohort of 746 Chinese adult patients].
Fu RF; Li HY; Xue F; Liu XF; Liu W; Huang YT; Chen YF; Zhang LY; Zhang L; Yang RC
Zhonghua Xue Ye Xue Za Zhi; 2017 Feb; 38(2):92-96. PubMed ID: 28279030
[No Abstract] [Full Text] [Related]
10. IPSET-Thrombosis Better Identifies Thrombosis-Free Survival: A Turkish Cohort.
Sevindik OG; Mersin S; Katgi A; Tunali S; Solmaz SM; Acar C; Alacacioglu I; Piskin O; Ozcan MA; Demirkan F; Undar B; Ozsan GH
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):e101-4. PubMed ID: 25790738
[TBL] [Abstract][Full Text] [Related]
11. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia.
Finazzi G; Carobbio A; Guglielmelli P; Cavalloni C; Salmoiraghi S; Vannucchi AM; Cazzola M; Passamonti F; Rambaldi A; Barbui T
Blood; 2014 Oct; 124(16):2611-2. PubMed ID: 25323688
[No Abstract] [Full Text] [Related]
12. Correlation between IPSET-t risk at diagnosis and subsequent hemorrhage in patients with essential thrombocythemia; a single institution experience.
Tosoni L; Liberi M; Morelli G; Zannier ME; Lazzarotto D; Filì C; Simeone E; Battaglia G; Callegari C; Fanin M; Damiani D; Fanin R; Tiribelli M
Ann Hematol; 2024 Feb; 103(2):443-448. PubMed ID: 38072850
[TBL] [Abstract][Full Text] [Related]
13. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
[TBL] [Abstract][Full Text] [Related]
14. Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis.
Barbui T; Thiele J; Carobbio A; Passamonti F; Rumi E; Randi ML; Bertozzi I; Vannucchi AM; Gisslinger H; Gisslinger B; Finazzi G; Ruggeri M; Rodeghiero F; Rambaldi A; Gangat N; Tefferi A
Blood; 2012 Jul; 120(3):569-71. PubMed ID: 22700720
[TBL] [Abstract][Full Text] [Related]
15. The new WHO classification for essential thrombocythemia calls for revision of available evidences.
Barbui T; Thiele J; Ferrari A; Vannucchi AM; Tefferi A
Blood Cancer J; 2020 Feb; 10(2):22. PubMed ID: 32098949
[TBL] [Abstract][Full Text] [Related]
16. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment.
Passamonti F; Thiele J; Girodon F; Rumi E; Carobbio A; Gisslinger H; Kvasnicka HM; Ruggeri M; Randi ML; Gangat N; Vannucchi AM; Gianatti A; Gisslinger B; Müllauer L; Rodeghiero F; d'Amore ES; Bertozzi I; Hanson CA; Boveri E; Marino F; Maffioli M; Caramazza D; Antonioli E; Carrai V; Buxhofer-Ausch V; Pascutto C; Cazzola M; Barbui T; Tefferi A
Blood; 2012 Aug; 120(6):1197-201. PubMed ID: 22740446
[TBL] [Abstract][Full Text] [Related]
17. Risk of thrombosis in essential thrombocythemia according to three prediction models: an external validation study.
Saelue P; Thongsukhsai P
J Thromb Thrombolysis; 2023 Apr; 55(3):527-535. PubMed ID: 36652138
[TBL] [Abstract][Full Text] [Related]
18. [Thrombotic events and significance of the IPSET thrombosis risk evaluation score in essential thrombocythaemia].
Pósfai É; Marton I; Nemes A; Borbényi Z
Orv Hetil; 2015 Apr; 156(14):558-63. PubMed ID: 25819149
[TBL] [Abstract][Full Text] [Related]
19. Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan.
Edahiro Y; Araki M; Inano T; Ito M; Morishita S; Misawa K; Fukuda Y; Imai M; Ohsaka A; Komatsu N
Eur J Haematol; 2019 Jun; 102(6):516-520. PubMed ID: 30977935
[TBL] [Abstract][Full Text] [Related]
20. Clinical Manifestations and Risk Factors for Complications of Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Duangnapasatit B; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Chai-Adisaksopha C; Tantiworawit A; Norasetthada L
Asian Pac J Cancer Prev; 2015; 16(12):5013-8. PubMed ID: 26163633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
